Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1994-4-7
|
pubmed:abstractText |
We have constructed a DNA plasmid encoding the full length complementary DNA for human carcinoembryonic antigen (CEA) driven by the cytomegalovirus early promoter/enhancer (plasmid DNA encoding human CEA) and demonstrated that this plasmid can function as a polynucleotide vaccine. This polynucleotide vaccine induced humoral and/or cellular immune responses specific for human CEA in all 5 immunized mice. Lymphoblastic transformation data with the use of enriched T-cell populations detected the presence of CEA-specific memory T-cells in 3 of 5 mice. Lymphocytes from 2 of 5 mice had interleukin 2/interleukin 4 release in response to CEA. CEA specificity was confirmed by the absence of reactivity to a control antigen and lack of CEA reactivity among mice vaccinated with a control plasmid encoding chloramphenicol acetyltransferase. Four of 5 mice vaccinated with plasmid DNA encoding human CEA demonstrated anti-CEA antibody responses. This immune response compared favorably with a positive control group of mice immunized with vaccinia-CEA by a dose and schedule previously shown to induce immunoprotection and therapy against a human CEA expressing syngeneic murine colon carcinoma model. Studies are ongoing to establish the construct, dose, and schedule to elicit optimal CEA-specific immune response as well as immunoprotection and therapy against human CEA expressing syngeneic murine adenocarcinoma models.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Carcinoembryonic Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Complementary,
http://linkedlifedata.com/resource/pubmed/chemical/Lymphokines,
http://linkedlifedata.com/resource/pubmed/chemical/Polynucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Synthetic
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
54
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1164-8
|
pubmed:dateRevised |
2006-5-1
|
pubmed:meshHeading |
pubmed-meshheading:8118800-Animals,
pubmed-meshheading:8118800-Antibody Formation,
pubmed-meshheading:8118800-Antibody Specificity,
pubmed-meshheading:8118800-Carcinoembryonic Antigen,
pubmed-meshheading:8118800-DNA, Complementary,
pubmed-meshheading:8118800-Dose-Response Relationship, Drug,
pubmed-meshheading:8118800-Humans,
pubmed-meshheading:8118800-Immunization,
pubmed-meshheading:8118800-Lymphocyte Activation,
pubmed-meshheading:8118800-Lymphocytes,
pubmed-meshheading:8118800-Lymphokines,
pubmed-meshheading:8118800-Mice,
pubmed-meshheading:8118800-Mice, Inbred C57BL,
pubmed-meshheading:8118800-Plasmids,
pubmed-meshheading:8118800-Polynucleotides,
pubmed-meshheading:8118800-Radiometry,
pubmed-meshheading:8118800-Vaccines, Synthetic
|
pubmed:year |
1994
|
pubmed:articleTitle |
Immune response to a carcinoembryonic antigen polynucleotide vaccine.
|
pubmed:affiliation |
Therapy Program, University of Alabama, Birmingham Comprehensive Cancer Center 35294.
|
pubmed:publicationType |
Journal Article
|